Stock XFOR X4 PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Market Closed - Nasdaq
Other stock markets
 03:59:52 2024-05-29 pm EDT 		5-day change 1st Jan Change
0.9283 USD -1.58% Intraday chart for X4 Pharmaceuticals, Inc. +3.52% +10.71%
May. 09 Sector Update: Health Care Stocks Higher Late Afternoon MT
May. 09 X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
AQ
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Sector Update: Health Care Stocks Higher Late Afternoon
MT
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise
MT
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc
CI
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
AQ
Transcript : X4 Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
X4 Pharmaceuticals: Q1 Earnings Snapshot
AQ
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating
MT
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
AQ
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome
CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
MT
Transcript : X4 Pharmaceuticals, Inc. - Special Call
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules
DJ
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
AQ
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome
CI
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XFOR Stock
  4. News X4 Pharmaceuticals, Inc.